Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

SELL
$0.24 - $0.92 $3,834 - $14,700
-15,979 Reduced 97.53%
405 $0
Q1 2024

May 07, 2024

SELL
$0.52 - $1.05 $202 - $409
-390 Reduced 2.33%
16,384 $15,000
Q4 2023

Feb 01, 2024

BUY
$0.6 - $1.65 $181 - $498
302 Added 1.83%
16,774 $12,000
Q3 2023

Nov 07, 2023

BUY
$1.67 - $3.33 $771 - $1,538
462 Added 2.89%
16,472 $28,000
Q2 2023

Aug 07, 2023

BUY
$2.83 - $4.94 $87 - $153
31 Added 0.19%
16,010 $45,000
Q1 2023

May 02, 2023

SELL
$4.89 - $12.27 $73,350 - $184,050
-15,000 Reduced 48.42%
15,979 $78,000
Q4 2022

Jan 30, 2023

BUY
$8.88 - $12.77 $44,213 - $63,581
4,979 Added 19.15%
30,979 $333,000
Q3 2022

Nov 08, 2022

BUY
$8.24 - $12.56 $44,405 - $67,685
5,389 Added 26.15%
26,000 $243,000
Q2 2022

Aug 04, 2022

SELL
$7.45 - $13.84 $81,868 - $152,087
-10,989 Reduced 34.78%
20,611 $188,000
Q1 2022

May 05, 2022

SELL
$9.94 - $12.65 $3,737 - $4,756
-376 Reduced 1.18%
31,600 $384,000
Q4 2021

Feb 02, 2022

SELL
$11.99 - $18.14 $1,067 - $1,614
-89 Reduced 0.28%
31,976 $389,000
Q3 2021

Nov 02, 2021

SELL
$11.55 - $16.06 $77,234 - $107,393
-6,687 Reduced 17.26%
32,065 $495,000
Q2 2021

Aug 02, 2021

BUY
$12.38 - $29.19 $4,357 - $10,274
352 Added 0.92%
38,752 $553,000
Q4 2019

Feb 05, 2020

SELL
$16.11 - $25.98 $1,611 - $2,598
-100 Reduced 0.26%
38,400 $619,000
Q3 2019

Nov 07, 2019

BUY
$18.28 - $26.91 $54,840 - $80,730
3,000 Added 8.45%
38,500 $704,000
Q2 2019

Aug 09, 2019

BUY
$17.68 - $21.57 $84,864 - $103,536
4,800 Added 15.64%
35,500 $763,000
Q4 2018

Feb 08, 2019

BUY
$12.45 - $23.47 $7,470 - $14,082
600 Added 1.99%
30,700 $399,000
Q2 2017

Aug 11, 2017

BUY
N/A
30,100
30,100 $463,000

Others Institutions Holding CARA

About Cara Therapeutics, Inc.


  • Ticker CARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,725,900
  • Market Cap $15M
  • Description
  • Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...
More about CARA
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.